Article

Apoptosis not only culprit in cell death

Apoptosis may be the best characterized form of programmed cell death-but it isn’t in isolation, said Joan W. Miller, MD.

New Orleans-Apoptosis may be the best characterized form of programmed cell death-but it isn’t in isolation, said Joan W. Miller, MD.

Alternative pathways are also at work, said Dr. Miller, chief and chairwoman, Department of Ophthalmology, Massachusetts Eye and Ear, Boston.   

Past research has focused on the mechanisms of cell death in the hopes of identifying therapeutic targets in degenerative retinal disease.

Previously, Dr. Miller said, apoptosis was thought to be the main mechanism of photoreceptor degeneration, but research shows it is not.

“Indeed, the caspase enzymes-which play a central role for inducing apoptosis-are activated in dying photoreceptor cells in experimental modes,” Dr. Miller said. “Paradoxically, inhibiting caspases doesn’t sufficiently protect against cell loss.”

Dr. Miller pointed out the involvement of other cell death mechanisms-specifically mentioning accumulating evidence demonstrating nonapoptotic forms of cell death, such as autophagy and necrosis, which are also regulated by specific molecular machinery, such as autophangy-related proteins and receptor-interacting protein RIP kinases, respectively.

“Certainly there are different pathogenesis,” she said. “There are different pathways, redundant and complimentary, for all these different diseases and some are overlapping.”

The key point, she said, is a research focus on combination therapy in order to achieve neuroprotection. By identifying alternative cell death pathways and understanding how to inhibit them, we can prevent vision loss in multiple eye disorders.

For more articles in this issue of Ophthalmology Times Conference Brief click here.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.